Cargando…

Treatment of Minimal Residual Disease in Breast Cancer: A Longitudinal Case Study

The presence of micrometastatic disease will ultimately determine the breast cancer-specific mortality of patients treated according to current guidelines. Minimal residual disease (i.e., occult tumor, not detected by conventional tests) may exist in two forms: a dormant form of only micrometastasis...

Descripción completa

Detalles Bibliográficos
Autor principal:	Murray, Nigel P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2017
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779321/ https://www.ncbi.nlm.nih.gov/pubmed/29383298 http://dx.doi.org/10.7759/cureus.1521

Ejemplares similares

Dynamics of Minimal Residual Disease in Neuroblastoma Patients
por: Uemura, Suguru, et al.
Publicado: (2019)

Liquid biopsies and minimal residual disease in myeloid malignancies
por: Allam, Sabine, et al.
Publicado: (2023)

Liquid biopsies and minimal residual disease in lymphoid malignancies
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Minimal residual disease in EGFR-mutant non-small-cell lung cancer
por: Bain, Nathan T., et al.
Publicado: (2022)

Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches
por: Cescon, David W., et al.
Publicado: (2022)

Epigenetic liquid biopsies for minimal residual disease, what’s around the corner?
por: Johnston, Andrew D., et al.
Publicado: (2023)

Non-invasive Molecular Detection of Minimal Residual Disease in Papillary Thyroid Cancer Patients
por: Almubarak, Hannah, et al.
Publicado: (2020)

Tumor microenvironment penetrating chitosan nanoparticles for elimination of cancer relapse and minimal residual disease
por: Mahmudi, Hossein, et al.
Publicado: (2022)

Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
por: Del Giudice, Ilaria, et al.
Publicado: (2019)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
por: Della Starza, Irene, et al.
Publicado: (2019)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management
por: Murray, Nigel P.
Publicado: (2018)

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma
por: Yao, Qiumei, et al.
Publicado: (2019)

The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice
por: Galimberti, Sara, et al.
Publicado: (2019)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

Editorial: Circulating molecular biomarkers: next-generation tools for monitoring minimal residual disease in cancer patients
por: Amoozgar, Zohreh, et al.
Publicado: (2023)

Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer
por: Jiang, Jiahong, et al.
Publicado: (2020)

Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches
por: Kostopoulos, Ioannis V., et al.
Publicado: (2020)

“Friends and foes” of multiple myeloma measurable/minimal residual disease evaluation by next generation flow
por: Pacelli, Paola, et al.
Publicado: (2022)

Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
por: Peng, Yan, et al.
Publicado: (2021)

The evolution of minimal residual disease: key insights based on a bibliometric visualization analysis from 2002 to 2022
por: Yu, Zhengyu, et al.
Publicado: (2023)

Plasma Circulating Tumor DNA Sequencing Predicts Minimal Residual Disease in Resectable Esophageal Squamous Cell Carcinoma
por: Liu, Tao, et al.
Publicado: (2021)

Integration of Inflammation-Immune Factors to Build Prognostic Model Predictive of Prognosis and Minimal Residual Disease for Hepatocellular Carcinoma
por: Xu, Xin, et al.
Publicado: (2022)

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy
por: Ferla, Valeria, et al.
Publicado: (2022)

Longitudinal Changes in Circulating Metabolites and Lipoproteins After Breast Cancer Treatment
por: Giskeødegård, Guro F., et al.
Publicado: (2022)

Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR
por: Yao, Qiumei, et al.
Publicado: (2021)

Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone
por: Murray, Nigel P, et al.
Publicado: (2020)

Re-Emergence of Minimal Residual Disease Detected by Flow Cytometry Predicts an Adverse Outcome in Pediatric Acute Lymphoblastic Leukemia
por: Wang, Yu, et al.
Publicado: (2021)

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
por: Romano, Alessandra, et al.
Publicado: (2019)

Minimal residual disease and circulating tumor cells in breast cancer
por: Ignatiadis, Michail, et al.
Publicado: (2011)

Impact of obesity on breast cancer recurrence and minimal residual disease
por: Ecker, Brett L., et al.
Publicado: (2019)

Metabolic memory underlying minimal residual disease in breast cancer
por: Radic Shechter, Ksenija, et al.
Publicado: (2021)

Leukemia Stem Cell Frequency at Diagnosis Correlates With Measurable/Minimal Residual Disease and Impacts Survival in Adult Acute Myeloid Leukemia
por: Kamel, Azza M., et al.
Publicado: (2022)

Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse
por: Murray, Nigel P, et al.
Publicado: (2019)

Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study
por: Di Lisa, Francesca Sofia, et al.
Publicado: (2023)

Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay
por: Farren, Timothy W., et al.
Publicado: (2020)

Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
por: Fan, Shuang, et al.
Publicado: (2022)

Use of Minimal Residual Disease Status to Reduce Uncertainty in Estimating Long-term Survival Outcomes for Newly Diagnosed Multiple Myeloma Patients
por: van Hest, Naomi, et al.
Publicado: (2023)

The role of the bone microenvironment in regulating myeloma residual disease and treatment
por: Dadzie, Terry G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2mj349em1277jhtdt9s8f1doka